A Phase 1, Open-label, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of TAK-385 Alone in Hormone Treatment- naïve Japanese Patients With Non-metastatic Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2018
Price : $35 *
At a glance
- Drugs Relugolix (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Takeda
- 31 Aug 2018 Biomarkers information updated
- 01 Jun 2017 Planned number of patients changed from 30 to 43.
- 01 Jun 2017 Status changed from active, no longer recruiting to completed.